BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 25272957)

  • 1. Proteins of the VEGFR and EGFR pathway as predictive markers for adjuvant treatment in patients with stage II/III colorectal cancer: results of the FOGT-4 trial.
    Thomaidis T; Maderer A; Formentini A; Bauer S; Trautmann M; Schwarz M; Neumann W; Kittner JM; Schad A; Link KH; Rey JW; Weinmann A; Hoffman A; Galle PR; Kornmann M; Moehler M
    J Exp Clin Cancer Res; 2014 Oct; 33(1):83. PubMed ID: 25272957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).
    Stahler A; Heinemann V; Giessen-Jung C; Crispin A; Schalhorn A; Stintzing S; Fischer von Weikersthal L; Vehling-Kaiser U; Stauch M; Quietzsch D; Held S; von Einem JC; Holch J; Neumann J; Kirchner T; Jung A; Modest DP
    Int J Cancer; 2016 Feb; 138(3):739-46. PubMed ID: 26284333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.
    Cascinu S; Georgoulias V; Kerr D; Maughan T; Labianca R; Ychou M
    Ann Oncol; 2003; 14 Suppl 2():ii25-9. PubMed ID: 12810454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current treatments and future perspectives in colorectal and gastric cancer.
    Wilke HJ; Van Cutsem E
    Ann Oncol; 2003; 14 Suppl 2():ii49-55. PubMed ID: 12810459
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
    Folprecht G; Lutz MP; Schöffski P; Seufferlein T; Nolting A; Pollert P; Köhne CH
    Ann Oncol; 2006 Mar; 17(3):450-6. PubMed ID: 16303861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Thomaidis T; Maderer A; Al-Batran SE; Kany J; Pauligk C; Steinmetz K; Schad A; Hofheinz R; Schmalenberg H; Homann N; Galle PR; Moehler M
    BMC Cancer; 2014 Jul; 14():476. PubMed ID: 24981311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
    McCleary NJ; Meyerhardt JA; Green E; Yothers G; de Gramont A; Van Cutsem E; O'Connell M; Twelves CJ; Saltz LB; Haller DG; Sargent DJ
    J Clin Oncol; 2013 Jul; 31(20):2600-6. PubMed ID: 23733765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.
    Ychou M; Hohenberger W; Thezenas S; Navarro M; Maurel J; Bokemeyer C; Shacham-Shmueli E; Rivera F; Kwok-Keung Choi C; Santoro A
    Ann Oncol; 2009 Dec; 20(12):1964-70. PubMed ID: 19567451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
    Tappenden P; Jones R; Paisley S; Carroll C
    Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.
    Bertagnolli MM; Niedzwiecki D; Compton CC; Hahn HP; Hall M; Damas B; Jewell SD; Mayer RJ; Goldberg RM; Saltz LB; Warren RS; Redston M
    J Clin Oncol; 2009 Apr; 27(11):1814-21. PubMed ID: 19273709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
    Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W
    Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Systemic treatment of colorectal cancers--factual standards and perspectives].
    Miron L
    Rev Med Chir Soc Med Nat Iasi; 2003; 107(4):752-8. PubMed ID: 14756014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study.
    Papadimitriou CA; Papakostas P; Karina M; Malettou L; Dimopoulos MA; Pentheroudakis G; Samantas E; Bamias A; Miliaras D; Basdanis G; Xiros N; Klouvas G; Bafaloukos D; Kafiri G; Papaspirou I; Pectasides D; Karanikiotis C; Economopoulos T; Efstratiou I; Korantzis I; Pisanidis N; Makatsoris T; Matsiakou F; Aravantinos G; Kalofonos HP; Fountzilas G
    BMC Med; 2011 Jan; 9():10. PubMed ID: 21281463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803.
    Sargent D; Shi Q; Yothers G; Van Cutsem E; Cassidy J; Saltz L; Wolmark N; Bot B; Grothey A; Buyse M; de Gramont A;
    Eur J Cancer; 2011 May; 47(7):990-6. PubMed ID: 21257306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
    Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
    J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New therapeutic options in chemotherapy of advanced colorectal cancer].
    Reimer P; Rückle-Lanz H
    Med Klin (Munich); 2001 Oct; 96(10):593-8. PubMed ID: 11715331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interferon-alpha in adjuvant treatment of colorectal carcinoma].
    Staib L; Link KH; Henne-Bruns D
    Kongressbd Dtsch Ges Chir Kongr; 2002; 119():142-5. PubMed ID: 12704877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
    Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
    Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?].
    Carnaghi C; Zucali P; Garassino I
    Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.